LYPD3

LYPD3

LYPD3 詳細

Molecule Name
Ly6/PLAUR domain-containing protein 3
分子の別称
LYPD3,MIG-C4,C4.4A
Drug Development Progress
治験薬の数1
市販薬剤の数0
研究&開発段階Phase 1 Clinical
ターゲットの別称
C4.4A,GPI-Anchored Metastasis-Associated Protein Homolog,2310061G07Rik,GPI-Anchored Metastasis-Associated Protein C4.4A Homolog,MIG-C4,UNQ491/PRO1007,Ly6/PLAUR domain-containing protein 3,LYPD3,Matrigel-Induced Gene C4 Protein,LY6/PLAUR Domain Containing 3
バックグランド
Ly6/PLAUR domain-containing protein 3 (LYPD3) is also known as MIG-C4 ,C4.4A, GPI-anchored metastasis-associated protein C4.4A homolog and Matrigel-induced gene C4 protein,which is a cell membrane protein containing two UPAR/Ly6 domains. LYPD3 is expressed in placenta, skin and urothelium. LYPD3 is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. LYPD3 play a role in supporting cell migration and it is not only probably involved in urothelial cell-matrix interactions, but also in tumor progression.

LYPD3 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
Lupartumab amadotinBAY-1129980Phase 1 ClinicalBayer AG
Neoplasms
詳細